Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data from β-thalassemia (...
Saved in:
Main Authors: | John Porter, Donald K. Bowden, Marina Economou, Jacques Troncy, Arnold Ganser, Dany Habr, Nicolas Martin, Adam Gater, Diana Rofail, Linda Abetz-Webb, Helen Lau, Maria Domenica Cappellini |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Anemia |
Online Access: | http://dx.doi.org/10.1155/2012/297641 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiac injury caused by iron overload in thalassemia
by: Chunxi Fu, et al.
Published: (2025-01-01) -
β-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life
by: Mehran Karimi, et al.
Published: (2012-01-01) -
Iron Chelation Therapy with Deferasirox Results in Improvement of Liver Enzyme Level in Patients with Iron Overload-Associated Liver Dysfunction
by: Yasuo Miura, et al.
Published: (2010-01-01) -
𝛽-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload
by: Luca Melchiori, et al.
Published: (2010-01-01) -
SOME ARTISTIC SIMILARITIES BETWEEN THE XO DANG EPIC AND THE BAHNAR EPIC
by: Ngoc Chien Nguyen, et al.
Published: (2023-02-01)